DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nucynta (Tapentadol Hydrochloride) - Summary

 
 



NUCYNTA SUMMARY

NUCYNTA® (tapentadol) is a mu-opioid receptor agonist, supplied in immediate-release film-coated tablets for oral administration, containing 58.24, 87.36 and 116.48 mg of tapentadol hydrochloride in each tablet strength, corresponding to 50, 75, and 100 mg of tapentadol free-base, respectively.

NUCYNTA® (tapentadol) is indicated for the management of moderate to severe acute pain in adults.


See all Nucynta indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Nucynta (Tapentadol)

Medical News Today: Complex regional pain syndrome: Watching others causes pain
Source: Featured Health News from Medical News Today [2016.12.02]
For patients with complex regional pain syndrome, simply watching someone else move can cause intense pain. An MRI scan study delves into the neuroscience.

Complex regional pain syndrome: Watching others causes pain
Source: Pain / Anesthetics News From Medical News Today [2016.12.02]
For patients with complex regional pain syndrome, simply watching someone else move can cause intense pain. An MRI scan study delves into the neuroscience.

Specially Designed Video Game Might Ease 'Phantom Limb' Pain
Source: MedicineNet Chronic Pain Specialty [2016.12.02]
Title: Specially Designed Video Game Might Ease 'Phantom Limb' Pain
Category: Health News
Created: 12/1/2016 12:00:00 AM
Last Editorial Review: 12/2/2016 12:00:00 AM

Should Pain Scores No Longer Be Vital?
Source: Medscape Anesthesiology Headlines [2016.12.01]
Asking patients how severe their pain is on a scale of 1 to 10 isn't vital to pain management, the AAFP says. What do you think?
Medscape Reader Polls

Can VR Games Soothe Phantom Limb Pain?
Source: MedPage Today Neurology [2016.12.01]
(MedPage Today) -- Pain reduced among arm amputees

more news >>

Published Studies Related to Nucynta (Tapentadol)

Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. [2014]
decrease in noxious heat stimulation)... CONCLUSIONS: Tapentadol's analgesic effect in chronic pain patients with DPN is

Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. [2014]
patients with hypertension... CONCLUSION: No clinically meaningful mean changes in heart rate or blood pressure

Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain. [2013]
OBJECTIVES: Constipation is a common side effect of opioid therapy. Tapentadol immediate release (IR) was better tolerated than oxycodone IR in 2 clinical trials involving patients with low back or osteoarthritis pain... DISCUSSION: Patient-reported bowel function associated with tapentadol IR treatment was similar to that associated with placebo (10-d trial) and significantly better than that associated with oxycodone IR treatment (10- and 90-d trials).

Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. [2012]
OBJECTIVE: To compare the effects of tapentadol-extended release versus oxycodone-controlled release for pain relief on productivity by combining evidence from different sources.

Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.

more studies >>

Clinical Trials Related to Nucynta (Tapentadol)

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Completed]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics [Completed]
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine [Completed]
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). *Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability. [Terminated]
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride PR treatment during defined periods of evaluation.

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability [Terminated]
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride prolonged release treatment during defined periods of evaluation.

more trials >>

Reports of Suspected Nucynta (Tapentadol) Side Effects

Hallucination (21)Drug Ineffective (20)Dizziness (20)Dyspnoea (20)Nausea (19)Confusional State (17)Feeling Abnormal (17)Depression (16)Withdrawal Syndrome (16)Anxiety (14)more >>


Page last updated: 2016-12-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015